Summary of Significant Accounting Policies (Tables)
|
3 Months Ended |
12 Months Ended |
Mar. 31, 2026 |
Dec. 31, 2025 |
| Accounting Policies [Line Items] |
|
|
| Schedule of Reconciliation Net Loss Per Ordinary Share Basic and Diluted |
The following table sets forth the computation of basic and diluted net income (loss) per common share:
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
13,367,096 |
|
|
$ |
(220,351 |
) |
Undistributed earnings allocated to participating securities |
|
|
(257,544 |
) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
13,367,096 |
|
|
$ |
(220,351 |
) |
Change in fair value of Simple Agreements for Future Equity |
|
|
(13,419,233 |
) |
|
|
— |
|
Undistributed earnings allocated to participating securities |
|
|
(241,038 |
) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for basic net income (loss) per share—common shares outstanding |
|
|
921,519 |
|
|
|
900,213 |
|
Effect of dilutive securities: |
|
|
|
|
|
|
|
|
Expected shares from SAFEs |
|
|
64,344 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
Denominator for diluted net loss per share—common shares outstanding |
|
|
985,863 |
|
|
|
900,213 |
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share—basic |
|
$ |
14.23 |
|
|
$ |
(0.24 |
) |
Net loss per share—diluted |
|
$ |
(0.30 |
) |
|
$ |
(0.24 |
) |
|
|
| Schedule Of Antidilutive Securities Excluded From Computation Of Earnings PerShare |
The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive (in common stock equivalent shares):
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
Unvested shares of restricted stock purchase agreements |
|
|
31,833 |
|
|
|
2,083 |
|
Expected shares from SAFE notes |
|
|
— |
|
|
|
22,358 |
|
|
|
|
|
|
|
|
|
|
Total potentially dilutive securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per common share because doing so would be anti-dilutive (in common stock equivalent shares):
|
|
|
|
|
|
|
|
|
| |
|
Year Ended
December 31,
2025 |
|
|
Period from
July 8, 2024
(inception) to
December 31,
2024 |
|
Unvested shares of restricted stock purchase agreements |
|
|
21,146 |
|
|
|
2,396 |
|
Expected shares from SAFE notes |
|
|
55,149 |
|
|
|
17,956 |
|
Total potentially dilutive securities |
|
|
76,295 |
|
|
|
20,352 |
|
|
| GIGCAPITAL7 CORP [Member] |
|
|
| Accounting Policies [Line Items] |
|
|
| Schedule of Class A common stock subject to possible redemption |
As of March 31, 2026 and December 31, 2025, the Class A ordinary shares subject to possible redemption reflected on the condensed consolidated balance sheets are reconciled in the following table:
|
|
|
|
|
Class A ordinary shares subject to possible redemption, December 31, 2025 |
|
$ |
211,537,310 |
|
|
|
|
|
|
Accretion of carrying value to redemption value—
three months ended March 31, 2026 |
|
|
1,869,218 |
|
|
|
|
|
|
Class A ordinary shares subject to possible redemption, March 31, 2026 |
|
$ |
213,406,528 |
|
|
|
|
|
|
|
As of December 31, 2025 and 2024, the Class A ordinary shares subject to possible redemption reflected on the consolidated balance sheet are reconciled in the following table:
|
|
|
|
|
| Gross proceeds |
|
$ |
200,000,000 |
|
| Less: |
|
|
|
|
| Fair value of public warrants at issuance |
|
|
(18,460,769 |
) |
| Ordinary share issuance costs |
|
|
(1,208,380 |
) |
| Plus: |
|
|
|
|
| Accretion of carrying value to redemption value—period from May 8, 2024 (inception) through December 31, 2024 |
|
|
22,757,853 |
|
| Class A ordinary shares subject to possible redemption, December 31, 2024 |
|
|
203,088,704 |
|
| Plus: |
|
|
|
|
| Accretion of carrying value to redemption value—year ended December 31, 2025 |
|
|
8,448,606 |
|
| Class A ordinary shares subject to possible redemption, December 31, 2025 |
|
$ |
211,537,310 |
|
|